Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 10, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 480,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 10, 2012.
- Price Range: Highest price paid was 1,442 pence per share; lowest price paid was 1,433 pence per share.
- Treasury Holdings (Settled): 504,465,427 shares (9.26% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,810,427 shares (10.24% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,940,585,398 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 480,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.24% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (504,465,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,940,585,398 shares in issue) for disclosure threshold assessments under Financial Services Authority rules.
- Check the settlement status of the 1,345,000 shares included in the "including shares which have been purchased but not yet settled" figure to reconcile the difference between settled and total treasury holdings.